Drug Search Results
More Filters [+]

Inosine

Alternative Names: inosine, rejuvesol
Latest Update: 2024-06-18
Latest Update Note: News Article

Product Description

Mechanisms of Action: Cytokine Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Algeria | Australia | Belgium | Bosnia | Brazil | Bulgaria | Canada | China | Colombia | Croatia | Czech | Ecuador | Egypt | France | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Italy | Korea | Latvia | Lithuania | Mexico | Morocco | New Zealand | Peru | Philippines | Poland | Portugal | Romania | Russia | Serbia | Singapore | Slovakia | Spain | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: POLYSAN Scientific & Technological Pharmaceutical Company
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Inosine

Countries in Clinic: Russia

Active Clinical Trial Count: 4

Highest Development Phases

Phase 3: Cholestasis, Intrahepatic|Craniocerebral Trauma|Head Injuries, Closed|Polyneuropathies|Stroke

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

RXA-II-III-Chol-2022

P3

Recruiting

Cholestasis, Intrahepatic

2025-05-01

41%

RXA-II-III-Chol-2022

P3

Recruiting

Cholestasis, Intrahepatic

2025-05-01

41%

RXA-II-III-Chol-2022

P3

Recruiting

Cholestasis, Intrahepatic

2025-05-01

41%

CTF-III-SR-2022

P3

Recruiting

Stroke

2024-09-01

48%

MITRA

P3

Recruiting

Craniocerebral Trauma|Head Injuries, Closed

2024-09-01

31%

CYLINDER

P3

Completed

Polyneuropathies

2021-03-29

86%

Recent News Events